Clinical Trial Update: 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PF-05082566 (4-1BB agonist) with trastuzumab emtansine or trastuzumab in advanced HER2-positive breast cancer; study completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PF-05082566 (4-1BB agonist)
• Trastuzumab (trastuzumab)
• Trastuzumab emtansine (ado-trastuzumab emtansine)

Snippet

Sponsor: George W. Sledge Jr. | Conditions: HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma | Phase 1 | Status: COMPLETED | Results posted: 2022-10-19